FibroBiologics (FBLG) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
FibroBiologics is the larger company by market cap ($7.7 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | SKYE |
|---|---|---|
| Share price | $1.11 | $1.68 |
| Market cap | $7.72M | $7.44M |
| 1-day change | -2.63% | +1.82% |
| EPS (TTM) | $-5.01 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.28 | $14.08 |
| 52-week low | $0.62 | $1.50 |
| Distance from 52-week high | -89.20% | -88.07% |
| Analyst consensus | none | none |
| Avg. price target upside | +1026.13% | +3947.62% |
| Average volume | 204.43K | 89.28K |
| Shares outstanding | 6.96M | 4.43M |
| Employees | 15 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Healthcare · Biotechnology · 15 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
FBLG vs SKYE FAQ
Which is bigger, FibroBiologics or Skye Bioscience?
FibroBiologics (FBLG) is larger, with a market capitalization of $7.72M compared with $7.44M for Skye Bioscience (SKYE).
Are FibroBiologics and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.